James Tullis

Myocor, Inc. develops products for the treatment of mitral regurgitation and congestive heart failure. It has two products in clinical trials that are designed to improve the pumping efficiency of the heart and thus improve the quality of life of patients. The company was founded in 1996 by Cyril J. Schweich and Todd Mortier and is headquartered in Maple Grove, MN.

Ikano Therapeutics Inc. (ITI) is a specialty pharmaceutical company focused on developing innovative therapeutics, with an emphasis on products treating disorders related to the central nervous system (CNS) for which there is proven, unsatisfied consumer need. They currently have two products in its clinical pipeline, with and others in formulation or preclinical development. Its goal is to become a leader in the field of specialty pharmaceuticals by applying its formulation expertise across a broad range of therapeutic areas to create new and differentiated products that improve safety, efficacy and convenience for patients, caregivers and health care professionals. ITI's fully integrated drug delivery platform combines proprietary formulation research, clinical and regulatory development, specialized delivery systems, clinical manufacturing and packaging. These capabilities and expertise enable them to develop its products efficiently and cost effectively. They intend to commercialize these products by marketing them themselves or partnering them with other companies. Its senior management team collectively has more than 100 years of experience in the pharmaceutical industry and extensive experience with development-stage companies. ITI supplements its own internal expertise with a variety of outside expert consultants, academic and industry and makes strategic use of outsourcing for development and commercial manufacturing.

Lord Abbett & Co. LLC (Lord Abbett) is an independent, SEC-registered investment advisor and mutual fund manager headquartered in Jersey City, New Jersey. Founded in 1929, Lord Abbett provides advisory services to a variety of institutional clients, the Lord Abbett Funds and other registered investment companies sponsored by third parties, the Lord Abbett UCITS Funds, the Lord Abbett Luxembourg Fund, other foreign funds, privately offered commingled funds and various separately managed accounts.

Synageva BioPharma's ultimate goal is to improve patient lives by providing access to breakthrough novel, next generation (i.e. significantly improved), and certain follow on protein therapeutics. Synageva's proprietary platform technologies, including SEP™, provide a number of sustainable competitive advantages for developing and commercializing these therapeutics including: high expression levels, more efficient purification processes, significantly reduced costs of production, rapid scalability, and consistency of end product. Its platform has already demonstrated its ability to produce a wide array of human therapeutic proteins including monoclonal antibodies (mAbs), cytokines, and other biotherapeutics. It has multiple compounds in development, including 2 monoclonal antibodies with enhanced ADCC activity, novel therapeutic proteins, and several cytokines including one with unique efficacy advantages. The commercialization strategy for these product candidates is designed to maximize its ability to rapidly develop and bring them to market so that they can address patients' unmet medical needs. The key elements of the strategy are to: 1. Establish partnerships to co-develop and commercialize select product candidates in large specialty markets 2. Independently develop and commercialize select novel product candidates that target high value orphan specialty markets 3. Establish partnerships to express proteins from other companies wanting to leverage the unique glycosylation advantages and other characteristics of the SEP™.

Atritech, Inc. is a private company that provides therapies to treat patients suffering from atrial fibrillation. They offer their services to clients who are at increased risk of stroke by offering permanent alternatives to medications. The company was founded in 2000 and is headquartered in Plymouth, MN.

ViaCell, Inc. provides and develops cellular medicine for the treatment of diseases. The firm develops medicines for treatment of cancer, genetic disorders, organ transplant tolerance, neurological disorders, and autoimmune diseases. The company was founded in April 2000 and is headquartered in Cambridge, MA.

SupplyPro, Inc. develops and manufactures point-of-use inventory control systems. It offers SupplyPad, an industrialized tablet that controls mobile and barcode-based materials; and SmartDrawer, a solution that provides control for small items, such as inserts, taps, drill bits, small tooling, fuses, switches and keys. The company was founded by Martin Bridges, Dean Rosenberg, William Holmes, and Craig K. Collins in 1995 and is headquartered in San Diego, CA.

LivHOME, Inc. provides home care services for seniors. It offers care management, caregiving and medical care services. The company was founded by Michael J. Nicholas and Steven Barlam in 1999 and is headquartered in Los Angeles, CA.

Chief Executives Organization, Inc. operates as a membership organization for charity. The CEO of the American company is Sheldon Elman.

Redco Corp. engages in the manufacturing of engineered industrial products. It operates through the following business segments: Process Flow Technologies, Payment and Merchandising Technologies, Aerospace and Electronics, and Engineered Materials. The Process Flow Technologies segment provides engineered process flow technologies to its customers. The Payment and Merchandising Technologies segment consists of Crane Payment Innovations and Merchandising Systems. The Aerospace and Electronics segment supplies components and systems, including original equipment and aftermarket parts, primarily for the commercial and military aerospace, and defense and space markets. The Engineered Materials segment manufactures fiberglass-reinforced plastic (FRP) panels and coils, primarily for use in the manufacturing of recreational vehicles, truck bodies, and truck trailers, with additional applications in commercial and industrial buildings. The company was founded by Richard Teller Crane on July 4, 1855, and is headquartered in Stamford, CT.

SafeOp Surgical, Inc. operates as a medical device company. It offers portable neuro monitoring devices that enable the detection of nerve damage, such as positioning effect, an injury to peripheral nerves related to patient positioning during surgery or prolonged sedation. The company was founded in 2011 and is headquartered in Hunt Valley, MD.

Part of Tullis Health Investors, Inc., Tullis Health Investors Fl, Inc. is a private company that provides investment services. The company is based in Palm Beach Gardens, FL.

Alphatec Spine, Inc. is focused on the design, development, manufacturing, and marketing of products for the surgical treatment of spine disorders, with a focus on treating condition affecting the aging spine. The firms product portfolio and pipeline include spinal disorder products and systems. The company was founded in 1990 and is headquartered in Carlsbad, CA.

The National Parks Conservation Association is a nonpartisan organization that has been working to safeguard national parks since 1919. The non-profit company is based in Washington. With over 1.6 million members and supporters, they aim to protect and preserve the most iconic and inspirational places in the country for future generations. The organization believes in engaging the next generation to ensure the protection of national parks, which is why they launched the Next Generation Advisory Council. The CEO of the American company is Theresa Pierno.

Lord Abbett Enhanced Floating Rate Fund operates as an organized, non-diversified, closed-end management investment company that offers its shares and is operated as an interval fund. Its investment objective is to seek a high level of current income. The company is headquartered in Jersey City, NJ.

Lord Abbett Special Situations Income Fund operates as an interval fund. It is a non-diversified, closed-end management investment firm. Its investment objective is total return and capital appreciation. The company was founded in 2021 and is headquartered in Jersey City, NJ.

Lord Abbett Credit Opportunities Fund is a closed-end management investment company that continuously offers its common shares and is operated as an interval fund. The company was founded on September 18, 2018 and is Headquartered in Jersey City, NJ.